Bronchiectasis News and Research

RSS
Bronchiectasis is a condition in which the lung’s airways (bronchi) are dilated, causing an accumulation of mucus. This, in turn, makes the patient more vulnerable to infection, which can cause permanent damage. Most affected patients are middle-aged.
Bayer's Amikacin Inhale and Ciprofloxacin DPI receive QIDP designation from FDA

Bayer's Amikacin Inhale and Ciprofloxacin DPI receive QIDP designation from FDA

International Biophysics files patent protection for revolutionary AffloVest

International Biophysics files patent protection for revolutionary AffloVest

BreathingSpace health facility improves quality of life for people with severe respiratory disease

BreathingSpace health facility improves quality of life for people with severe respiratory disease

Lung-damaging bacterium turns body's antibody response in its favor

Lung-damaging bacterium turns body's antibody response in its favor

Aradigm begins Pulmaquin Phase III study for treatment of non-CF BE

Aradigm begins Pulmaquin Phase III study for treatment of non-CF BE

Aradigm’s common shares approved for listing on NASDAQ Capital Market

Aradigm’s common shares approved for listing on NASDAQ Capital Market

Aradigm receives QIDP designation for its inhaled antibiotic candidate, Pulmaquin

Aradigm receives QIDP designation for its inhaled antibiotic candidate, Pulmaquin

Aradigm reports total revenue of $6.6 million for Q1 2014

Aradigm reports total revenue of $6.6 million for Q1 2014

Bayer's Ciprofloxacin DPI receives FDA orphan drug designation for NCFB treatment

Bayer's Ciprofloxacin DPI receives FDA orphan drug designation for NCFB treatment

Insmed reports results from ARIKAYCE phase 2 trial for treatment resistant NTM lung infections

Insmed reports results from ARIKAYCE phase 2 trial for treatment resistant NTM lung infections

Common cholesterol-lowering drugs provide relief to patients suffering from chronic lung disease

Common cholesterol-lowering drugs provide relief to patients suffering from chronic lung disease

Aradigm reports record revenue of $4.6M in fourth quarter 2013

Aradigm reports record revenue of $4.6M in fourth quarter 2013

FDA OOPD grants orphan drug designation to Alitair's Erdosteine for treatment of bronchiectasis

FDA OOPD grants orphan drug designation to Alitair's Erdosteine for treatment of bronchiectasis

Electromed gets FDA clearance to market next generation SmartVest Airway Clearance System

Electromed gets FDA clearance to market next generation SmartVest Airway Clearance System

Queen's University is lead partner in £6M global research program to develop new ways to treat CF

Queen's University is lead partner in £6M global research program to develop new ways to treat CF

GERD prevalence raised even in mild–moderate COPD, bronchiectasis

GERD prevalence raised even in mild–moderate COPD, bronchiectasis

New study reveals damaging effects of road-side pollution in people with bronchiectasis

New study reveals damaging effects of road-side pollution in people with bronchiectasis

Grifols signs worldwide licensing agreement for Aradigm's Pulmaquin

Grifols signs worldwide licensing agreement for Aradigm's Pulmaquin

Study shows benefit of azithromycin in patients with non-CF bronchiectasis

Study shows benefit of azithromycin in patients with non-CF bronchiectasis

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.